Entity family
Named diseases, disorders, syndromes, injuries, and health conditions. Examples include epilepsy, diabetes, stroke.
This disease is selected. Its supporting articles are shown below.
…y for hematological malignancies but faces critical barriers in solid tumors due to tumor antigen heterogeneity and on-target, off-tumor tox…
… in tens to hundreds of patients (figure 1b). For patients with melanoma, Morpheus predicted that combinatorial perturbation to the CXCL…
…ch success in hematological cancers, ACT efficacy is limited in solid tumors due to poor tumor infiltration and immunosuppressive tumor micr…
…eptides by comprehensively profiling the immunopeptidome of two GBM cell lines GL261 and CT2A, and cross-presenting APCs. We catego…
…in a Phase 1 trial ( NCT06789172), as a novel immunotherapy for solid tumors, both as a standalone treatment and in combination with anti-PD…
…e production. OX40-mAbs were widely tested for immunotherapy in solid tumors (agonist), and autoimmune diseases (antagonist), with well-know…
…calls to mind the paradoxical observations of the regression of solid tumors concurrent with S. pyogenes infections (Coley’s toxin). We subm…
…nical success in hematologic malignacies, yet their efficacy in solid tumors is influenced by cellular heterogeneity of the immune and strom…
…as 23.3 for ccRCC (kidney), 1.9 for DLBCL (spleen), and 3.6 for MESO (lung). In comparative analyses, CD70 expression in ccRCC was s…
…ing endothelial, fibroblasts, and immune cells across different solid tumors. No changes in total CD39 protein expression levels were observ…
…hages (CAR-M) represent a promising immunotherapy candidate for solid tumors, by combining targeted antigen recognition with innate immune f…
…nd A major hurdle for effective engineered T cell therapies for solid tumors indications is the identification and targeting of a tumor-asso…